Greenland Mines GRML

NASDAQ GRML

$4.19 -0.16 (-3.68%)

At close: Sep 9, 2026 · 4:00 PM EDT

Key Stats

Add ratio to table…

About

Greenland Mines Ltd develops essential medicines for the treatment of chronic diseases, including cancer, cardiovascular, and neurodegenerative disorders. The company operates a generic drug portfolio that includes 5 market approved anti cancer drugs authorized for sale in Germany. These drugs are part of the FOLFOX and FOLFIRI regimens used to treat metastatic colorectal, gastric and lung cancers. Greenland Mines Ltd also holds a biosimilar biologics platform focused on oncology, comprising 2 off patent antibodies obtained from Reliance Life Sciences that serve as alternatives to reference therapeutics such as rituximab, trastuzumab and bevacizumab. In addition, the company maintains a proprietary gene therapy platform that uses the Klotho protein to address neurodegenerative conditions like Alzheimer’s disease and amyotrophic lateral sclerosis. In March 2026, Greenland Mines Ltd completed the acquisition of Greenland Mines Corp., which adds the development and mining of critical and precious minerals to its business activities.

We generate revenue primarily from the sale of its 5 market approved anti cancer drugs in Germany, which are distributed to hospitals and pharmacies for use in chemotherapy regimens. Revenue also comes from the 2 off patent biosimilar antibodies, which are marketed to oncology providers as cost effective alternatives to branded biologics. The gene therapy platform, while still in pre clinical development, is expected to create future revenue through licensing agreements, partnership collaborations, or eventual product sales after regulatory approval. Additionally, the recently acquired mining subsidiary is positioned to generate income from the extraction and sale of critical and precious minerals to industrial customers. The company may also earn royalties from its licensed technologies, including a 3 percent net sales fee on certain gene therapy products under its agreements with the Autonomous University of Barcelona.

In the oncology biosimilars market, Greenland Mines Ltd competes with large generic drug manufacturers such as Pfizer, Mylan, Amgen, Teva Pharmaceutical Industries, Celltrion, Sandoz and other firms that produce biosimilar versions of rituximab, trastuzumab and bevacizumab. The company’s advantage lies in its exclusive licensing agreement with Reliance Life Sciences, which grants access to proprietary manufacturing know how and regulatory data for these biosimilar candidates. In the gene therapy field, the company faces competition from academic groups and biotech firms pursuing neurodegenerative treatments, including Unity Biotechnology, but it holds an exclusive worldwide license from the Autonomous University of Barcelona for the secreted Klotho s KL protein, providing a proprietary edge in Alzheimer’s and ALS therapy development. The mining division, although newly entered, operates in a sector dominated by major multinational miners, yet it seeks to differentiate itself by targeting critical minerals that are essential for high technology and green energy applications.

The company serves hospitals, outpatient oncology clinics, and patients receiving chemotherapy through its generic drug and biosimilar oncology products. Its gene therapy candidates are intended for neurology departments, memory disorder centers and specialized treatment facilities that focus on Alzheimer’s disease and amyotrophic lateral sclerosis. The mining division will supply critical and precious minerals to manufacturers of electronic components, producers of renewable energy equipment and industrial users requiring these materials for production processes.

Investment Thesis

▲ Bull case

Greenland Mines (GRML) is strategically positioned to capitalize on a structural revaluation of its Skaergaard Project due to sustained higher long-term gold prices, which the company's May 2026 metal price sensitivity analysis confirms could increase PdEq grades by 45% for Indicated and 55% for Inferred resources using only its existing 2022 NI 43-101 block model. This uplift, driven predominantly by gold’s contribution to in-situ value despite its lower ounce count, translates to a potential resource base of 16.58 Moz PdEq Indicated and 21.92 Moz PdEq Inferred under the high-price scenario—directly aligning with the $4,800–$4,900/oz realized prices recently reported by senior gold producers like Newmont, Barrick, Agnico Eagle, and Kinross. Crucially, this sensitivity exercise does not require new drilling or geological reinterpretation; it merely reflects how the same physical resource becomes markedly more valuable under prevailing market conditions, offering investors a near-term catalyst for resource re-rating without execution risk. The company’s emphasis that this is "the kind of scale and price leverage that long-term institutional and strategic partners look for" signals awareness that GRML’s asset is transitioning from speculative optionality to a tangible development candidate in the eyes of capital allocators seeking exposure to critical metals with geopolitical relevance.
Beyond commodity leverage, GRML is actively constructing a transatlantic value chain that could derisk development and enhance long-term economics, a dimension underappreciated by the market focused solely on resource size. Its recent membership in the European Raw Materials Alliance (ERMA), alongside its North Atlantic Processing Site Strategy targeting low-carbon geothermal-powered refining in Iceland, creates a tangible pathway to secure off-take and financing from EU-aligned industrial consumers under the Critical Raw Materials Act. This is not merely symbolic—ERMA functions as an investment pipeline for projects aligned with EU supply chain resilience goals, and GRML’s dual-listing as a US-registered Nasdaq firm with 80% ownership via a Greenlandic subsidiary positions it uniquely to bridge North American capital markets with European policy objectives. The company’s participation in forums like the EIT RawMaterials Summit and CMI Summit 5, where it engages directly with OEMs, technology partners, and sovereign wealth funds, suggests it is advancing beyond exploration into early-stage value-chain negotiation—potentially unlocking strategic partnerships, streamlined permitting, or even precursor funding ahead of a full feasibility study.
The Skaergaard Project’s scale and polymetallic complexity offer optionality that extends well beyond palladium-gold-platinum, with historical indicators of recoverable vanadium, gallium, iron, and titanium—metals increasingly vital to defense, energy transition, and high-technology supply chains. While these by-products are not yet in the NI 43-101 resource, GRML’s engagement of GTK Mintec for integrated metallurgical and pilot-scale processing in Finland demonstrates a deliberate effort to evaluate full-spectrum recovery, moving beyond simple PGM-Au extraction to maximize value per tonne mined. This approach aligns with the "Mined Once – Utilised in Full" theme GRML is promoting at European forums, signaling a shift from narrow precious metal focus to holistic resource utilization—a strategy that could significantly improve project economics by spreading capital costs across multiple revenue streams. Given that the company has already secured funding for its 2026 field, drill, and bulk-sample campaign, and is testing open-pit and bulk-mining scenarios alongside underground methods, it is systematically de-risking development pathways while enhancing the project’s appeal to ESG-conscious investors and industrial partners seeking responsibly sourced, multi-commodity supply.

Greenland Mines (GRML) is strategically positioned to capitalize on a structural revaluation of its Skaergaard Project due to sustained higher long-term gold prices, which the company's May 2026 metal price sensitivity analysis confirms could increase PdEq grades by 45% for Indicated and 55% for Inferred resources using only its existing 2022 NI 43-101 block model. This uplift, driven predominantly by gold’s contribution to in-situ value despite its lower ounce count, translates to a potential resource base of 16.58 Moz PdEq Indicated and 21.92 Moz PdEq Inferred under the high-price scenario—directly aligning with the $4,800–$4,900/oz realized prices recently reported by senior gold producers like Newmont, Barrick, Agnico Eagle, and Kinross. Crucially, this sensitivity exercise does not require new drilling or geological reinterpretation; it merely reflects how the same physical resource becomes markedly more valuable under prevailing market conditions, offering investors a near-term catalyst for resource re-rating without execution risk. The company’s emphasis that this is "the kind of scale and price leverage that long-term institutional and strategic partners look for" signals awareness that GRML’s asset is transitioning from speculative optionality to a tangible development candidate in the eyes of capital allocators seeking exposure to critical metals with geopolitical relevance.
Beyond commodity leverage, GRML is actively constructing a transatlantic value chain that could derisk development and enhance long-term economics, a dimension underappreciated by the market focused solely on resource size. Its recent membership in the European Raw Materials Alliance (ERMA), alongside its North Atlantic Processing Site Strategy targeting low-carbon geothermal-powered refining in Iceland, creates a tangible pathway to secure off-take and financing from EU-aligned industrial consumers under the Critical Raw Materials Act. This is not merely symbolic—ERMA functions as an investment pipeline for projects aligned with EU supply chain resilience goals, and GRML’s dual-listing as a US-registered Nasdaq firm with 80% ownership via a Greenlandic subsidiary positions it uniquely to bridge North American capital markets with European policy objectives. The company’s participation in forums like the EIT RawMaterials Summit and CMI Summit 5, where it engages directly with OEMs, technology partners, and sovereign wealth funds, suggests it is advancing beyond exploration into early-stage value-chain negotiation—potentially unlocking strategic partnerships, streamlined permitting, or even precursor funding ahead of a full feasibility study.
The Skaergaard Project’s scale and polymetallic complexity offer optionality that extends well beyond palladium-gold-platinum, with historical indicators of recoverable vanadium, gallium, iron, and titanium—metals increasingly vital to defense, energy transition, and high-technology supply chains. While these by-products are not yet in the NI 43-101 resource, GRML’s engagement of GTK Mintec for integrated metallurgical and pilot-scale processing in Finland demonstrates a deliberate effort to evaluate full-spectrum recovery, moving beyond simple PGM-Au extraction to maximize value per tonne mined. This approach aligns with the "Mined Once – Utilised in Full" theme GRML is promoting at European forums, signaling a shift from narrow precious metal focus to holistic resource utilization—a strategy that could significantly improve project economics by spreading capital costs across multiple revenue streams. Given that the company has already secured funding for its 2026 field, drill, and bulk-sample campaign, and is testing open-pit and bulk-mining scenarios alongside underground methods, it is systematically de-risking development pathways while enhancing the project’s appeal to ESG-conscious investors and industrial partners seeking responsibly sourced, multi-commodity supply.

▼ Bear case

Greenland Mines (GRML) faces substantial execution risk as it advances the Skaergaard Project without having completed any preliminary economic assessment (PEA), pre-feasibility, or feasibility study, meaning the heightened resource grades from its metal price sensitivity analysis remain purely theoretical and untested against real-world costs. The May 2026 SLR Consulting analysis explicitly states it holds all technical and economic inputs constant from the 2022 NI 43-101 model—including the 1.43 g/t PdEq cut-off grade, underground mining constraint, and absence of metallurgical recovery factors—meaning the 45% to 55% PdEq grade uplift assumes identical processing efficiency and operating costs despite vastly different metal prices. In reality, scaling up to exploit the higher-grade zones identified in the sensitivity case (e.g., H5 horizon jumping from 2.85 to 6.56 g/t PdEq Indicated) would likely require revised mine plans, potentially higher energy consumption for deeper or more complex extraction, and unproven metallurgical flowsheets for a polymetallic ore containing variable amounts of sulphides, silicates, and potential penalty elements. Without a PEA to establish baseline capex, opex, or recovery rates, investors have no way to assess whether the projected resource expansion translates to viable economics, making the current valuation dependent on continued gold price strength rather than demonstrable project advancement.
GRML’s dual-division structure—pairing the capital-intensive, long-lead Skaergaard mineral project with the speculative cell and gene therapy business via Klotho’s KLTO-202 for ALS—creates strategic misalignment and resource allocation tension that could distract from core mining objectives. While management frames both divisions as complementary under an experienced leadership team, the biotech arm relies on volatile clinical trial outcomes, regulatory approvals, and uncertain reimbursement pathways, with recent news highlighting only incremental diagnostic patent progress (e.g., Australian claims for s-KL use) rather than near-term therapeutic milestones. This exposes GRML to the risk of being valued as a sum-of-parts where the mining asset is discounted for biotech-related execution risk, or worse, where capital and managerial focus are diverted to prolonging a cash-intensive biotech venture with limited revenue visibility. The lack of segmented reporting in press releases further obscures whether funding for the 2026 Skaergaard field campaign is being diluted by biotech burn rate, a concern amplified by the company’s reliance on forward-looking statements about "future commercial operations" across both divisions without clarifying near-term cash flow priorities.
Despite proactive engagement with European alliances like ERMA and participation in transatlantic forums, GRML remains exposed to significant geopolitical and regulatory uncertainty in developing a major mining project in Greenland, where infrastructure limitations, evolving environmental governance, and Indigenous consultation requirements could delay or alter project scope. The company’s emphasis on securing icebreaker vessels like M/V Argus and building a North Atlantic corridor via low-carbon processing in Iceland reveals awareness of logistical fragility, yet it does not address how Greenland’s nascent regulatory framework—particularly around large-scale resource projects—might respond to increased foreign investment or environmental scrutiny. While ERMA membership signals alignment with EU critical raw materials goals, it does not guarantee preferential treatment, permitting streamlining, or financial support under the Critical Raw Materials Act, which still requires formal project applications subject to political discretion. Furthermore, the company’s reliance on external partners like GTK Mintec (Finland), WSP (environmental baseline), and IceTugs (logistics) introduces coordination risk across jurisdictions, and any disruption in these partnerships—due to funding shifts, technical disagreements, or regional policy changes—could impede the 2026 field campaign’s objectives, leaving GRML with advanced planning but no de-risked path to production.

Greenland Mines (GRML) faces substantial execution risk as it advances the Skaergaard Project without having completed any preliminary economic assessment (PEA), pre-feasibility, or feasibility study, meaning the heightened resource grades from its metal price sensitivity analysis remain purely theoretical and untested against real-world costs. The May 2026 SLR Consulting analysis explicitly states it holds all technical and economic inputs constant from the 2022 NI 43-101 model—including the 1.43 g/t PdEq cut-off grade, underground mining constraint, and absence of metallurgical recovery factors—meaning the 45% to 55% PdEq grade uplift assumes identical processing efficiency and operating costs despite vastly different metal prices. In reality, scaling up to exploit the higher-grade zones identified in the sensitivity case (e.g., H5 horizon jumping from 2.85 to 6.56 g/t PdEq Indicated) would likely require revised mine plans, potentially higher energy consumption for deeper or more complex extraction, and unproven metallurgical flowsheets for a polymetallic ore containing variable amounts of sulphides, silicates, and potential penalty elements. Without a PEA to establish baseline capex, opex, or recovery rates, investors have no way to assess whether the projected resource expansion translates to viable economics, making the current valuation dependent on continued gold price strength rather than demonstrable project advancement.
GRML’s dual-division structure—pairing the capital-intensive, long-lead Skaergaard mineral project with the speculative cell and gene therapy business via Klotho’s KLTO-202 for ALS—creates strategic misalignment and resource allocation tension that could distract from core mining objectives. While management frames both divisions as complementary under an experienced leadership team, the biotech arm relies on volatile clinical trial outcomes, regulatory approvals, and uncertain reimbursement pathways, with recent news highlighting only incremental diagnostic patent progress (e.g., Australian claims for s-KL use) rather than near-term therapeutic milestones. This exposes GRML to the risk of being valued as a sum-of-parts where the mining asset is discounted for biotech-related execution risk, or worse, where capital and managerial focus are diverted to prolonging a cash-intensive biotech venture with limited revenue visibility. The lack of segmented reporting in press releases further obscures whether funding for the 2026 Skaergaard field campaign is being diluted by biotech burn rate, a concern amplified by the company’s reliance on forward-looking statements about "future commercial operations" across both divisions without clarifying near-term cash flow priorities.
Despite proactive engagement with European alliances like ERMA and participation in transatlantic forums, GRML remains exposed to significant geopolitical and regulatory uncertainty in developing a major mining project in Greenland, where infrastructure limitations, evolving environmental governance, and Indigenous consultation requirements could delay or alter project scope. The company’s emphasis on securing icebreaker vessels like M/V Argus and building a North Atlantic corridor via low-carbon processing in Iceland reveals awareness of logistical fragility, yet it does not address how Greenland’s nascent regulatory framework—particularly around large-scale resource projects—might respond to increased foreign investment or environmental scrutiny. While ERMA membership signals alignment with EU critical raw materials goals, it does not guarantee preferential treatment, permitting streamlining, or financial support under the Critical Raw Materials Act, which still requires formal project applications subject to political discretion. Furthermore, the company’s reliance on external partners like GTK Mintec (Finland), WSP (environmental baseline), and IceTugs (logistics) introduces coordination risk across jurisdictions, and any disruption in these partnerships—due to funding shifts, technical disagreements, or regional policy changes—could impede the 2026 field campaign’s objectives, leaving GRML with advanced planning but no de-risked path to production.

Peer group

Peer Comparison

Companies in the Generic Drugs

S.No.	Ticker	Company	match	Market Cap	P/E	P/S	Total Debt (Qtr)
1	TEVA	Teva Pharmaceutical Industries Ltd	primary	42.84 Bn	61.56	2.47	16.59 Bn
2	VTRS	Viatris Inc	primary	19.13 Bn	-46.58	1.30	13.35 Bn
3	RDY	Dr Reddys Laboratories Ltd	primary	9.91 Bn	785.46	2.70	0.81 Bn
4	AMRX	Amneal Pharmaceuticals, Inc.	primary	5.51 Bn	25.57	1.77	2.67 Bn
5	BHC	Bausch Health Companies Inc.	primary	2.30 Bn	-2.11	0.21	21.61 Bn
6	ALVO	Alvotech	primary	1.50 Bn	-5.39	4.38	1.34 Bn
7	ANIP	Ani Pharmaceuticals Inc	primary	1.49 Bn	13.80	1.52	0.30 Bn
8	AMPH	Amphastar Pharmaceuticals, Inc.	primary	1.00 Bn	12.03	1.38	0.61 Bn

Greenland Mines GRML

About

Investment Thesis

Peer Comparison

Create an account

Sign In

Reset Password